Trivora ®

- The first therapeutic equivalent to Triphasil®*1

Pharmacokinetic studies demonstrate bioequivalence throughout all three phases†1

First tablet sequence:

Second tablet sequence:

Third tablet sequence:

- Optimal packaging for ease of patient use

Easy-to-use credit-card pill pack

SAFETY INFORMATION
Women who use oral contraceptives (OCs) should be strongly advised not to smoke due to the increased risk of cardiovascular side effects. Serious risks reported with the use of OCs include blood clots, stroke, and heart attacks. OCs are contraindicated in women with thrombophlebitis, thromboembolic disorders, breast cancer, hepatic or estrogen-dependent neoplasia, cerebrovascular or coronary artery disease, jaundice, or undiagnosed genital bleeding. OCs do not protect against HIV infection (AIDS) or other sexually transmitted diseases.

Please see full Prescribing Information.
*Triphasil is a registered trademark of Wyeth-Ayerst Laboratories.
†Based on the results of open-label, randomized pharmacokinetic studies repeated at intervals of at least 4 weeks.
Reference: 1. Data on file, Watson Pharma, Inc.